Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein.
about
Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary managementAdvanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adultsDeterminants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancerThe impact of moderate to severe renal insufficiency on patients with acute myocardial infarction.Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adultsPlasma apolipoprotein C-III metabolism in patients with chronic kidney disease.A systems view of type 2 diabetes-associated metabolic perturbations in saliva, blood and urine at different timescales of glycaemic controlInflammation and vascular calcification.Plasma Pentosidine and Its Association with Mortality in Patients with Chronic Kidney Disease.Dialysis patients and cardiovascular problems: can technology solve the complex equation?Dialysis patients and cardiovascular problems: Can technology help solve the complex equation?Effects of exercise in renal transplant recipients.Homocysteine-induced macrophage inflammatory protein-2 production by glomerular mesangial cells is mediated by PI3 Kinase and p38 MAPKStirring the Pot: Can Dietary Modification Alleviate the Burden of CKD?C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).Inflammation, vitamin D and dendritic cell precursors in chronic kidney disease.C-reactive protein induces interleukin-6 and thrombospondin-1 protein and mRNA expression through activation of nuclear factor-ĸB in HK-2 cells.Skin autofluorescence: a pronounced marker of mortality in hemodialysis patients.Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes.Serum CRP levels in pre-dialysis patients.Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis.Advanced glycation end products and β(2)-microglobulin as predictors of carpal tunnel syndrome in hemodialysis patients.Advanced glycation end products and soluble receptor as markers of oxidative stress in children on hemodialysis.Skin and plasma autofluorescence during hemodialysis: a pilot study.Usefulness of pretransplant aortic arch calcification evaluation for kidney transplant outcome prediction in one year follow-up.
P2860
Q26781156-4BDFCB95-8935-48A4-A46C-E54DAFBA8F9EQ34217710-2B798876-968E-4B3E-AA57-A6D81B2CE2A4Q34426525-29DFEC9F-B719-49E9-B783-9F25D79047E8Q35094783-E0F28D4C-6AA8-4CF3-A15B-C47A4E2A2239Q35173430-42406F94-0878-456B-97D9-3D6A814F3751Q35771163-0086CFF6-4C8F-4945-A035-267D9EDE2185Q35842441-A68EF9B0-2A61-4F8A-88AC-573AC35485AFQ35997682-A93C0325-AF75-4384-91B8-BFCEEA07BDAAQ36152748-5DE7D0B9-AFB6-4A3E-8F8D-F2657D4E415EQ36315162-31424A12-85EA-41FF-87CB-066E6E05AB51Q36345531-45F1249C-584D-4222-9ED3-8CC963FC3564Q37195461-B1AD708E-A0E9-4DFB-8EA1-57F67DA4FCB8Q37393918-67E69159-45A4-4C94-B9C4-DF97DAB38767Q37729792-2373543B-765D-44BC-951A-26CAABE66240Q38819669-11015550-FC12-4F8A-94DB-B19615B5EDADQ38842023-F8740826-56D4-41C7-84AE-60808B8EB042Q39416709-38D4795F-F168-44CD-ACA5-AAC79F9F0989Q42240020-EE8BED91-674C-45BD-B7C3-4040641631C9Q46211956-827A81B0-C3E0-47D8-844C-01B0500EB976Q46733498-CAC70889-503F-4FB3-BCE9-8C61D9CA8154Q47216784-B7ED9375-DFA3-4AAD-96AE-46D8D158E9F6Q47346953-2EDCFDCD-3681-47FB-930D-92920ED7D471Q51331971-9A8378A7-49B2-49BE-BBE8-957A9F23E4E5Q53790164-1EBEAF47-1E1A-4C21-AB3F-2659A8D0F668Q54688869-7DCE520B-D069-424A-B4D0-2730F2E7B0B5Q55438288-FB27B235-2411-4205-87F2-6B067D47B3FF
P2860
Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Potential cardiovascular risk ...... s, and the C-reactive protein.
@en
Potential cardiovascular risk ...... s, and the C-reactive protein.
@nl
type
label
Potential cardiovascular risk ...... s, and the C-reactive protein.
@en
Potential cardiovascular risk ...... s, and the C-reactive protein.
@nl
prefLabel
Potential cardiovascular risk ...... s, and the C-reactive protein.
@en
Potential cardiovascular risk ...... s, and the C-reactive protein.
@nl
P2093
P1433
P1476
Potential cardiovascular risk ...... s, and the C-reactive protein.
@en
P2093
Andreas Müller
Günter Stein
Jens Gerth
Marco Wolf
Martin Busch
Sybille Franke
Toshimitsu Niwa
Undine Ott
P304
P356
10.1111/J.1523-1755.2004.00736.X
P407
P577
2004-07-01T00:00:00Z
P5875
P6179
1036069624